A study published online Oct. 30 in the journal JAMA Oncology found that hormonal contraception is an important risk factor for the development of breast cancer in younger women.
Researchers from the Department of Immunology, Genetics, and Pathology at the University of Uppsala, Sweden, followed more than 2 million adolescent and premenopausal women for about 13 years. The study design was a population-based cohort study conducted using the Swedish, national registers.
The goal of the study was to determine if breast cancer risk differs by the content of hormonal contraceptives. The authors of the study analyzed the use of hormonal contraceptives, categorized by hormone formulations and route of administration.
In the population of adolescents and women younger than 50 years studied, 16,385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with an increased breast cancer risk 24%. Higher risk was associated with oral desogestrel-only contraceptives as well as implants containing etonogestrel and desogestrel. Medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, did not have a statistically significant increased risk.
The findings of this cohort study are significant, considering that breast cancer incidence is rising around the globe in premenopausal women.
The authors of the study concluded that “findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives”. The authors support informed consent in the prescription of contraception. It is crucial to ensure that every woman is fully aware of the risks and benefits associated with the use of potent hormonal contraceptive methods.
This entry was posted
on Wednesday, December 3rd, 2025 at 11:51 pm and is filed under News & Commentary, Uncategorized.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.
Physicians Healed$4.95
Sexual Wisdom$6.00
Humanae Vitae$2.95
Does The Birth Control Pill Cause Abortions?$4.50
Good News about Sex & Marriage$13.99
Sterilization Reversal - A Generous Act of Love$10.00
Breast Cancer Risk in Adolescents and Premenopausal Women and Contraception
A study published online Oct. 30 in the journal JAMA Oncology found that hormonal contraception is an important risk factor for the development of breast cancer in younger women.
Researchers from the Department of Immunology, Genetics, and Pathology at the University of Uppsala, Sweden, followed more than 2 million adolescent and premenopausal women for about 13 years. The study design was a population-based cohort study conducted using the Swedish, national registers.
The goal of the study was to determine if breast cancer risk differs by the content of hormonal contraceptives. The authors of the study analyzed the use of hormonal contraceptives, categorized by hormone formulations and route of administration.
In the population of adolescents and women younger than 50 years studied, 16,385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with an increased breast cancer risk 24%. Higher risk was associated with oral desogestrel-only contraceptives as well as implants containing etonogestrel and desogestrel. Medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, did not have a statistically significant increased risk.
The findings of this cohort study are significant, considering that breast cancer incidence is rising around the globe in premenopausal women.
The authors of the study concluded that “findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives”. The authors support informed consent in the prescription of contraception. It is crucial to ensure that every woman is fully aware of the risks and benefits associated with the use of potent hormonal contraceptive methods.
This entry was posted on Wednesday, December 3rd, 2025 at 11:51 pm and is filed under News & Commentary, Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.